NCT02865447 is a clinical trial of total hip arthroplasty implant in Joint Disease, sponsored by MicroPort Orthopedics Inc..

Who is sponsoring NCT02865447?

NCT02865447 is sponsored by MicroPort Orthopedics Inc..

What drugs are being tested in NCT02865447?

Interventions in NCT02865447: total hip arthroplasty implant.

What condition does NCT02865447 study?

NCT02865447 studies Joint Disease.

Is NCT02865447 still recruiting?

NCT02865447 is currently completed. Last updated 2 August 2022.

Last reviewed 2022-08-02 · How we verify

NCT02865447

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Bone Mineral Density Changes After Total Hip Replacement: A Two-Year Clinical and DXA Analysis

Completed Last updated 2 August 2022

What this trial tests

trial testing total hip arthroplasty implant in Joint Disease in 25 participants. Completed in 24 August 2020.

Timeline

9 March 2017

Primary endpoint
24 August 2020

24 August 2020

Quick facts

Lead sponsor	MicroPort Orthopedics Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	25
Start date	9 March 2017
Primary completion	24 August 2020
Estimated completion	24 August 2020
Sites	1 location across United States

Drugs / interventions tested

total hip arthroplasty implant

Conditions studied

Joint Disease — all drugs for Joint Disease →

Sponsor

MicroPort Orthopedics Inc.

Who can join

Adults 21 to 80, any sex, with Joint Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sponsor is conducting this post-market study to evaluate the clinical outcome and femoral bone mineral density (BMD) changes associated with the PROFEMUR® PRESERVE hip stem when used as indicated for primary total hip arthroplasty in patients with osteoarthritis of the hip joint.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Joint Disease

Currently open trials in the same condition.

NCT06713902 — Extracellular Vesicles in Fibrin Gel for Cartilage Repair · recruiting
NCT04037735 — RSA-RCT: Attune S+ TKA Versus Sigma TKA · NA · recruiting
NCT03865667 — Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Preserve Femoral Stem · active not recruiting

Other MicroPort Orthopedics Inc. trials

Trials by the same sponsor.

NCT07391592 — Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate · active not recruiting
NCT04147559 — Post Market Clinical Follow-Up Study for PROFEMUR® Preserve Classic Femoral Stem · enrolling by invitation
NCT04145401 — Post Market Clinical Follow-Up Study- EVOLUTION® Revision CCK · enrolling by invitation
NCT03865667 — Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Preserve Femoral Stem · active not recruiting
NCT03450733 — Wright Medical Technology Metal-on-Metal 522 Post-Market Surveillance Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02865447 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MicroPort Orthopedics Inc.
Last refreshed: 2 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02865447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing